Merck & Co., Inc. (MRK) vs Palantir Technologies Inc. (PLTR)

Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.

Palantir Technologies is an artificial intelligence, data analytics, and automated decision-making company that helps organizations improve efficiency through data-driven operations. It serves commercial customers through its Foundry platform and government clients through Gotham. Palantir works exclusively with organizations in Western-allied nations and maintains the right to decline engagements it views as contrary to Western values. Founded in 2003, the company became publicly traded in 2020.